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Background: Primary hepatic angiosarcoma is a very rare malignancy with a poor prognosis. While surgical
resection has been validated as curative choice, most cases are diagnosed too late for resection. Nonetheless,
treatment protocols have not been established and also there are very few reports on the clinical features and
treatment outcomes.
Patients and methods: Among 11 939 patients diagnosed with primary hepatic tumors from January 1985 to
December 2007 at two centers, five patients were diagnosed with primary hepatic angiosarcoma. We analyzed
patients’ demographics, tumor characteristics, treatment modality, and outcomes using imaging, serology, and
pathology.
Results: All five patients were diagnosed at advanced stage with distant metastases. The most common symptom
was abdominal pain. The levels of the tumor markers were within the normal range and serological tests were negative
for hepatitis B and C viruses. Two of four patients who received chemotherapy died <3 months after diagnosis, but the
other two patients survived >6 months.
Conclusions: A combination of chemotherapy resulted in an improved outcome for two of four patients, suggesting
the potential usefulness of palliative chemotherapy to improve survival. This case study may aid in planning
chemotherapy for patients with advanced hepatic angiosarcoma.
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introduction
Primary hepatic angiosarcoma is a rare malignancy
accounting for only 0.1%–2% of all malignant primary liver
tumors [1, 2]. This is a highly malignant and rapidly
progressing vascular tumor of endothelial cell origin. It has
been reported that the median survival with this cancer is
<6 months without treatment, and most patients die
within a year of diagnosis. While environmental carcinogens,
such as vinyl chloride, thorium dioxide, and arsenic, are
known to cause primary hepatic angiosarcoma [1, 3–5],
exposure to these chemicals is very rare and the major
causes remain unknown. Pathological examination has
proven to be the best approach for confirming primary
hepatic angiosarcoma [6–8], while imaging such as
computed tomography and magnetic resonance is not
conclusive, but can be helpful. The most frequent
symptoms are abdominal pain, weakness, fever, and
weight loss, but these are also found with other types of
tumors [1, 9]. Due to the absence of early specific
symptoms and signs, diagnosis and treatment are often
delayed. Collectively, delayed diagnosis and the highly
malignant characteristics of the tumor, including
chemoresistance, result in a poor prognosis. The unusual
presentation of the tumor and the diagnostic difficulties
combined with high mortality make early recognition
very important.
When the lesion is confined to one lobe of the liver
without any metastases, hepatic resection has proven to be
beneficial and there have been reports of occasional
long-term survivors after resection [10–12]. However, the
majority of hepatic angiosarcoma is unresectable at
diagnosis. Palliative chemotherapy is indicated for
patients with unresectable angiosarcoma, but an effective
chemotherapeutic agent has not been established. In
addition, due to the rareness of this cancer, optimal
management for patients is poorly characterized. In
Korea, five primary hepatic angiosarcomas were
reported [13–17], but the clinical outcomes after
treatment were not described in detail. Here, we present
the clinical manifestations of advanced primary
hepatic angiosarcoma with distant metastases and the
treatment outcomes from various combinations of
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chemotherapeutic agents including ifosfamide, doxorubicin,
and paclitaxel [18–20].
patients and methods
patients
We conducted retrospective case reviews of patients diagnosed with
primary hepatic angiosarcoma at two centers in Korea. At the Yonsei
University Health System (YUHS), there were four cases (0.04%) of
advanced stage primary hepatic angiosarcoma out of 11 415 primary
hepatic carcinoma patients from January 1985 to December 2007. At the
Kyunghee University East-West Neo Medical Center (KHNMC), there was
one case of advanced stage primary hepatic angiosarcoma (0.19%) out of
524 primary hepatic carcinoma patients from June 2006 to December 2007.
clinical evaluation of tumor
Demographic and clinicopathological information was obtained from the
patients’ medical records and included the following parameters: age,
gender, environmental history, presenting symptoms, Eastern Cooperative
Oncology Group (ECOG) performance status, characteristics of primary
hepatic angiosarcoma, laboratory profiles including complete blood count,
liver function tests, carcinoembryonic antigen (CEA), CA 19-9 and a-
fetoprotein (AFP), hepatitis B and C profile, and treatment modality.
Characteristics of the primary hepatic angiosarcoma included pathologic
type, tumor number, existence of tumor rupture, and metastatic sites. The
pathological staging was determined according to the AJCC criteria (sixth
edition, 2002).
follow-up and assessments
Overall survival (OS) was defined as the period of time from the initial
diagnosis of primary hepatic angiosarcoma to death from any cause or last
follow-up. An evaluation of the response to chemotherapy was carried out
during the entire course of the chemotherapy using Response Evaluation
Criteria in Solid Tumors [21].
results
clinical characteristics
The baseline characteristics of the patients are presented in
Table 1. All five patients were men with a median age of 45
years (range 41–69 years). Three patients (patients 1–3) had
a grade 2 or 3 ECOG performance status and the other two
patients (patients 4 and 5) had a grade 1 ECOG performance
status. None of the patients had a significant history of
exposure to specific carcinogens that were related to primary
hepatic angiosarcoma. Right upper quadrant abdominal pain
was the most common presenting symptom and in patients
with lung metastases, the initial symptom was hemoptysis. All
patients had multiple hepatic lesions with bilobar distribution
and extrahepatic distant metastases. Extrahepatic metastatic
lesions were found in the spleen, lung, and bone. One patient
had hemoperitoneum due to the rupture of angiosarcoma [17].
Table 2 shows the laboratory profiles of the patients enrolled
in this study. Thrombocytopenia was observed in three
patients, 83 000, 52 000, and 80 000. There was anemia in two
patients, one of whom had hepatic rupture. Serologic tests
for hepatitis B and C were carried out in four patients and all
were negative. All patients were in Child-Pugh class A by
liver function test. Two patients developed mild jaundice in
which a total bilirubin level was <3 mg/dl. Aspartate
transaminase (AST) and alanine transaminase (ALT) were <100
IU/l except in one patient who experienced rapid deterioration
from multiorgan failure. Tumor markers, such as CEA, CA
19-9, and AFP, were all within normal ranges.
pathology
All tumors were microscopically evaluated to analyze the
pathologic characteristics as well as to confirm diagnosis. Figure 1
Table 1. Characteristics of patients with primary hepatic angiosarcoma
Patient Sex/age ECOG Carcinogen
exposure
Presenting symptoms No. of
hepatic mass
Metastases Hepatic
rupture
OS (days) Cause of death
1 Male/44 3 No RUQ pain; leg edema Multiple Spleen Yes 8 Hepatic rupture
2 Male/69 2 No Hemoptysis Multiple Lung No 49 PD
3 Male/49 2 No RUQ pain; ascites; DOE Multiple Spleen No 86 PD
4 Male/41 1 No Chest discomfort Multiple Pericardium No 474 PD
5 Male/45 1 No RUQ pain Multiple Bone No 222 PD
ECOG, Eastern Cooperative Oncology Group; OS, overall survival; RUQ, right upper quadrant; PD, disease progression; DOE, dyspnea on exertion.
Table 2. Initial laboratory profile of patients enrolled
Patient WBC
(/ll)
Hb
(g/dl)
Platelet
(·/103 ll)
Total bilirubin
(mg/dl)
Albumin
(g/dl)
AST/ALT
(IU/l)
Prothrombin
time (INR/s)
AFP/CEA/CA19-9
(IU/ml)/(ng/ml)/(U/ml)
Hepatitis
B and C
1 9900 9.2 83 000 1.4 3.6 212/140 1.87/20.1 <3/ND/ND Negative
2 7950 11.5 123 000 1.0 3.7 35/50 1.02/12.5 2.83/1.52/33.2 ND
3 7170 8.0 52 000 2.5 3.0 97/35 1.39/15.7 3.81/ND/12 Negative
4 7540 11.7 191 000 2.4 3.8 25/35 1.15/13.2 0.9/1.46/4.2 Negative
5 6900 12.5 80 000 1.1 4.2 40/29 1.24/14.9 2.6/<1.5/10.16 Negative
WBC, white blood cell; Hb, hemoglobin; AST, aspartate transaminase; ALT, alanine transaminase; AFP, a-fetoprotein; CEA, carcinoembryonic antigen; ND
indicates not done.
Annals of Oncology original article
Volume 20 | No. 4 | April 2009 doi:10.1093/annonc/mdn702 | 781
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on January 14, 2014
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
showed the representative pathologic findings from patients 3, 4,
and 5. Hematoxylin and eosin stain of all patients showed
malignant pleomorphic tumor forming vessel-like structures,
suggesting angiosarcoma. Compared with patient 3, patients 4
and 5 showed relatively well-differentiated findings. Positive
immunohistochemical staining for CD31, favoring angiosarcoma,
was observed in patients 3, 4, and 5. In addition, the
immunohistochemical staining for factor VIII was positive in
patients 3 and 5. These results confirm that tumors from all three
patients are angiosarcoma (Table 3).
treatment outcomes
All cases were surgically unresectable at diagnosis due to
multiple hepatic tumor masses and metastases to other organs.
Radiotherapy was not conducted for any of the patients because
angiosarcoma is known to be radioresistant [22]. Therefore,
palliative chemotherapy is the only available treatment option.
Figure 2 shows the treatment outcomes as well as
chemotherapy regimens for the individual patients. Patient 1
died of multiple organ failure caused by initial
hemoperitoneum with rapid progression without any chance to
receive chemotherapy. This previously reported case was
diagnosed after death via autopsy [17]. The other four patients
received palliative chemotherapy as summarized in Figure 2.
The initial first-line chemotherapy for the three patients
(patients 2, 3, and 4) at YUHS was a doxorubicin/carboplatin/
5-fluorouracil regimen, which is composed of 5-fluorouracil
(5-FU) and carboplatin in combination with transhepatic
artery infusion of doxorubicin. These patients had progressive
disease (PD) after one to two cycles and two patients (patients 2
and 3) died of PD. Meanwhile, patient 4 received a second
palliative ifosfamide/doxorubicin (IA) regimen chemotherapy
composed of ifosfamide infusion (i.v.) every 3 weeks,
accompanied by doxorubicin infusion via hepatic artery every 5
weeks. After five cycles, patient 4 received six more cycles of
chemotherapy with both ifosfamide and doxorubicin by i.v.
due to inaccessibility to the hepatic artery. The best response
for patient 4 was stable disease (SD) (less than a 30% reduction
and less than a 20% increase in the sum of the long diameter
of target lesions and the appearance of no new lesions) and
survival was observed for 16 months after diagnosis (Figure 2
and Figure 3A–E).
Table 3. Immunohistochemical staining results in patients 3, 4, and 5
Patient no. Immunohistochemical stain
Positive Negative
3 CD31, factor VIII, reticulin cytokeratin, CD34
4 CD31, CD34 CEA, c-Kit, demin
5 CD31, factor VIII, Ki-67 c-Kit, elastin fiber,
masson trichrome, reticulin
Figure 1. Pathologic findings in patients 3, 4, and 5. Pathology findings in patient 3 [A, hematoxylin and eosin (H&E) stain, ·200; B, immunohistochemical
stain of factor VIII, ·200] show malignant pleomorphic tumor forming vessel-like structures, suggestive of angiosarcoma and factor VIII positive. Pathology
findings in patient 4 (C, H&E stain ·200; D, immunohistochemical stain of CD31, ·100) show malignant spindle cell tumor, favoring angiosarcoma and
CD31 positive. Pathology findings in patient 5 (E, H&E stain ·200; F, immunohistochemical stain of CD34, ·200) show malignant spindle cell tumor,
favoring angiosarcoma and CD34 positive. Among other immunohistochemical stains, both cytokeratine and carcinoembryonic antigen, marker for
carcinoma, were negative (data not shown, see Table 3).
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Patient 5 at KHNMC was treated with an IA regimen as the
first-line chemotherapy and had SD lasting 4 months. After five
cycles of the IA regimen, the patient developed PD and was
changed to paclitaxel. After the first cycle of paclitaxel
chemotherapy, the chemotherapy regimen was replaced with
bevacizumab due to PD. Finally, the patient died of PD after
the first cycle of bevacizumab, with an OS period of 9 months
(Figure 2 and Figure 3F–J).
The median OS in these patients was 86 days (range 8–439
days). Even though three patients died <3 months after
diagnosis, the remaining two patients (patients 4 and 5)
received second or third lines of chemotherapy regimens and
survived for 16 and 9 months, respectively.
discussion
Primary hepatic angiosarcoma progresses rapidly and therefore,
most cases are diagnosed at an advanced stage. Less than 20%
of patients can receive surgery [23, 24], which has been proven
to be beneficial, and occasional long-term survivors after
resection have been reported [12, 25]. However, the majority of
hepatic angiosarcomas are not resectable at diagnosis. All
patients enrolled in our study were unresectable due to
advanced stage cancer with multiple and systemic metastases.
Primary hepatic angiosarcoma shows a strong male
predominance with a male to female ratio of 3 : 1 [9], which
may be due to a direct link between angiosarcoma and
exposure to industrial chemicals. While the patients in our
study were all male, none of them had a prior history of
exposure to known carcinogenic agents. The chemicals that
have been shown to be clear and definitive causative factors are
thorotrast, polyvinyl chloride, and arsenic powder [3, 4].
However, the chance of being exposed to these carcinogens has
decreased in recent years and the majority of hepatic
angiosarcomas are not related to the above etiologic causes.
Hepatitis is endemic to Asia and might induce or stimulate
liver fibrosis, so we analyzed the potential relationship
between hepatitis and hepatic angiosarcoma. However, none
of the patients in our study were positive for a hepatitis
B or C marker.
Initial laboratory findings in our cases are not specific as
shown in previous reports. Some reports showed that liver
function tests were not largely abnormal except mild
hyperbilirubinemia, mild elevated AST/ALT [2, 9, 15,
25–27]. We think our liver function test profile is relatively
similar with that of previously reported. Thrombocytopenia,
which was shown in 50%, and anemia are relatively common
characteristic of hepatic angiosarcoma and may be related
Figure 2. Chemotherapy regimen and treatment outcomes for the individual patients.
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to consumption of clotting factors [2, 14, 15, 27]. It seems
that these clotting abnormalities and the vascular nature
of the primary hepatic angiosarcoma lead to catastrophic
rupture of hepatic angiosarcoma and induce the
intraabdominal bleeding in about one-fourth of all cases.
Our case has relatively large portion of thrombocytopenia
(80%). Anemia is commonly related to the rupture of
tumor and intraabdominal bleeding.
To improve the survival of hepatic angiosarcoma, early
detection and resection are supposed to be factors leading to
the good prognosis. Therefore, it is important to be
suspicious of hepatic angiosarcoma when it is combined with
nonspecific symptoms such as right upper quadrant pain and
mild fever. It should also be noted that the liver function test
and tumor markers such as CEA, AFP, and CA 19-9 are not
specific as mentioned previously. Therefore, liver biopsy
could be necessary to confirm the tumor, although imaging
studies are helpful.
There are only a few reports showing the median survival for
patients without treatment which is <6 months [2, 9, 15, 17].
Even though there is little evidence that chemotherapy is
efficacious for primary hepatic angiosarcoma in unresectable
hepatic angiosarcoma, palliative chemotherapy could be an
option. Moreover, there are few reports about treatment
regimens and clinical outcomes for patients with an advanced
stage of primary hepatic angiosarcoma. Table 4 shows the
summary of treatment modality and clinical outcomes of
primary hepatic angiosarcoma. There are various
Figure 3. Computed tomography images of patient 4 (A–E) and patient 5 (F–J). (A, B) Initial finding before chemotherapy. (A) Malignant pericardial
effusion due to pericardial metastasis is observed. (C) Progressive disease (PD) finding after second doxorubicin, carboplatin, 5-fluorouracil chemotherapy.
Newly developed multiple intrahepatic metastatic nodules are observed in both lobes of the liver. (D) Stable disease (SD) finding after first ifosfamide,
doxorubicin (IA). Peribiliary and liver parenchymal necrosis are progressed in both lobes of liver. In contrast, there is no newly developed lesion or
progression evidence. (E) Marked progression of liver nodules in size and number. Newly developed multiple nodules of spleen are observed compatible
with metastasis. (F) Initial finding before chemotherapy. (G, H) SD finding after second, fourth IA chemotherapy, respectively. (I) PD finding after fifth IA
chemotherapy. (J) PD finding after paclitaxel treatment.
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chemotherapeutic regimens, which implied no established and
efficacious regimens. (Table 4) Even if these data are not
sufficient for providing detail clinical information including
stage, median survival, the kinds of chemotherapeutic
regimens, these may be helpful to recognize status of treatment
modality, poor prognosis, rarity, and clinical manifestation [18,
28, 29]. In some reports with survival data, the median survival
of primary hepatic angiosarcoma range from 5 to 14 months.
Especially, Dannaher et al. have reported the favorable
outcomes after chemotherapy for four patients. The
chemotherapy regimen consisted of i.v. doxorubicin 60 mg/m2
every 3–4 weeks, with cyclophosphamide and methotrexate
added in three patients [26]. This previous study reported an
objective improvement in three of four patients and SD in the
other patient. Survival in the four patients from the time of
diagnosis was 11, 13, 15, and 53 months. The reason for the
differences between the report and our study might be the fact
that their study included asymptomatic patients of good
performance status diagnosed by screening examinations for
industrial employees. However, there was no information about
distant metastases, extension of liver involvement, and stage in
this study compared with our study. In the other hand, all
patients in our study were diagnosed with metastatic primary
hepatic angiosarcoma ineligible for surgery, which stresses the
aggressive behavior of this tumor.
Until now, there has been little information on treatment,
no established chemotherapy regimen, and few reports about
clinical outcomes of chemotherapy for advanced primary
hepatic angiosarcoma. As there is no standard regimen, we
selected chemotherapeutic agents that have been used for
various sarcomas. Based on previous studies, we used
a variety of chemotherapeutic agents such as 5-FU,
carboplatin, doxorubicin, ifosfamide, paclitaxel, and
bevacizumab [18–20, 29]. In our study, patients 2, 3, and 4
received 5-FU and carboplatin in combination with
transhepatic artery infusion of doxorubicin. In addition,
based on previous experience in treating hepatocellular
carcinoma, we combined transhepatic artery infusion of
doxorubicin for local control. Two patients failed the
treatment, but one patient received the salvage chemotherapy
for a significant period of time. In patient 5, paclitaxel and
bevacizumab were used in the second and third salvage
chemotherapy after five cycles of IA regimen failure. The
rationale behind the use of paclitaxel is that it appears to
be useful for unresectable or metastatic angiosarcoma [20,
30–34]. Paclitaxel has antiangiogenic and apoptotic effects.
Because the origin of angiosarcoma is the endothelial cell,
it is conceivable that the antiangiogenic activity of paclitaxel
is efficacious in angiosarcoma. Recently, phase II trial of
weekly paclitaxel for metastatic and unresectable
angiosarcoma presented that the efficacy and tolerable
toxicity showing that median time to progression was 4
months and median OS was 8 months [29]. A novel biology-
based approach will be needed to improve the current
systemic chemotherapy for patients with unresectable
angiosarcoma [35–38]. Bevacizumab, which is known to
have an antiangiogenic effect, was used as an alternative
chemotherapy in angiosarcoma because angiosarcoma is
rich in vascularity due to its endothelial cell origin and
showed high expression for vascular endothelial growth
factor. However, this chemotherapeutic approach in our
study was not efficacious because the patient was in an
advanced stage with being refractory to several treatments.
Some newer biologic therapies including antiangiogenic
therapies such as bevacizumab or sorafenib may be effective
theoretically against sarcoma or angiosarcomas [36, 37].
However, the majority of these results are those for patients
with scalp and face angiosarcoma and limited in numbers
[20, 30, 32–34, 39].
As we mentioned previously, conventional chemotherapy
and external radiotherapy for primary hepatic angiosarcoma
had limitation due to low efficacy, the intrinsic radioresistance
of this tumor, and the relative sensitivity of nontumorous liver
tissue [40, 41]. Therefore, we need to consider the alternative
Table 4. Summary of treatment modality and clinical outcomes of primary hepatic angiosarcoma including previous reports and current study
Author Period PHA Stage Treatment modalities Clinical outcomes
Dannaher et al. 1974–1976 PHA (n = 4) NA ADR, cyclophosphamide, MTX MS: 14 months
Molina et al. 1979–1997 PHA (n = 5) Resectable (n = 2);
unresectable (diffuse)
(n = 3)
Resection followed by adjuvant
chemotherapy (etoposide/ifosfamide)
(n = 1); IA ADR/DTIC (n = 1); no
treatment (n = 2); resection (n = 1)
MS: 6 months
Fayette et al. 1980–2004 PHA (n = 7)/AS
(n = 204)
NA NA 5-Year survival
rate: 0%
Weitz et al. 1981–2004 PHA (n = 5)/LS
(n = 30)
Resectable (n = 3);
unresectable (n = 2)
Resection (2 R0, 1 R1/2) (n = 3);
NA (n = 2)
R0 (n = 2): die
within 11 months
Abraham et al. 1980–2006 PHA (n = 1)/AS
(n = 82)
Unresectable (diffuse)
(n = 1)
NA NA
Penel et al. 2005–2006 PHA (n = 3)/AS
(n = 30)
Unresectable (metastatic)
(n = 3)
Weekly paclitaxel NA
Kim et al.
(current study)
1985–2007 PHA (n = 5) Unresectable (metastatic)
(n = 5)
Variable chemotherapy MS: 5 months
PHA, primary hepatic angiosarcoma; AS, angiosarcoma; LS, liver sarcoma; ADR, adriamycin; MTX, methotrexate; DTIC, darcabazine; MS, median survival;
diffuse, diffuse liver involvement; NA, not available.
Annals of Oncology original article
Volume 20 | No. 4 | April 2009 doi:10.1093/annonc/mdn702 | 785
 at Y
O
N
SEI U
N
IV
ERSITY
 M
ED
ICA
L LIBRA
RY
 on January 14, 2014
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
approaches such as selective internal radiation therapy (SIRT)
using intrahepatic arterial infusion of 90Yttrium microspheres
[42, 43]. In SIRT, the pure beta-emitting isotope 90Yttrium is
composed of millions of microspheres that are injected into the
hepatic artery or one of its branches. The radioactive
microspheres deposit in the feeding vasculature of the tumor,
resulting in the delivery of intense local radiation to tumor but
relative sparing of normal liver parenchyma [44, 45]. There are
abundant data of SIRT for liver metastases arising from
colorectal cancer, neuroendocrine tumor, and primary
hepatocellular carcinoma and so on, and the reports
represented promising survival [46]. These factors can be
rationale that SIRT using intrahepatic arterial 90Yttrium apply
to primary hepatic angiosarcoma. So we think SIRT has
potential role in treatment primary hepatic angiosarcoma and
can apply to this tumor carefully.
Little is mentioned about prognostic factors for primary
hepatic angiosarcoma. As shown in previous reports,
unresectable, advanced stage of primary hepatic angiosarcoma
had especially poor prognosis. In addition, poor survival
was noted in cases of hemoperitoneum by tumor rupture
[2, 17, 47]. In cases of resectable hepatic angiosarcoma, it
has been suggested that positive resection margins, but not
tumor size, were associated with early recurrence and poor
survival [22]. Based on our study, we suggest that it is
worthwhile to consider the major determinants of prognosis or
survival after chemotherapy of unresectable primary hepatic
angiosarcoma. From the pathologic findings, patients 4 and 5
showed well-differentiated patterns compared with patient 3,
indicating that pathologic differentiation might be related to
survival. ECOG could also be another determinant associated
with OS. In our study, the OS of patients 3, 4, and 5 was 86,
474, and 222 days, respectively, and their functional classes
were ECOG 2, ECOG1, and ECOG1, respectively, which
suggests that a relatively better ECOG leads to an increased
long-term survival. Therefore, both pathologic differentiation
and ECOG status could be used as prognostic factors to predict
the treatment outcome from hepatic angiosarcoma.
Until now, there is no established chemotherapy regimen for
primary hepatic angiosarcoma. Here, we suggest that the use of
5-FU–carboplatin accompanied with doxorubicin or
ifosfamide–doxorubicin could be an efficient regimen.
Furthermore, it might be reasonable to prevent hepatic
angiosarcoma rupture during treatment [47, 48] because
hemoperitoneum requires urgent diagnosis and management.
In our chemotherapy regimen, doxorubicin infusion via
hepatic artery appeared to be helpful in preventing hepatic
angiosarcoma rupture and bleeding, although hepatic artery
chemoinfusion still needs to be studied in more detail. Lastly,
favorable pathology and ECOG with tolerable to palliative
chemotherapy appears to be prognostic factors for this tumor.
We anticipate that our study will be a useful reference for
developing a treatment for patients with advanced primary
hepatic angiosarcoma.
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